工银前沿医疗股票A、工银医疗保健股票基金经理分别为赵蓓、丁洋。 简历显示，赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现任研究部副总监、医疗保健研究团队负责人,2014年11 月18日至今,担任工银医疗保健行业股票型基金基金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞信前 沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票型证券投资基金基金经理。2020年05月20日至2022年6月14 日担任工银瑞信科技创新6个月定期开放混合型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基金经 理。 | ○ 基金经理:赵蓓 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 累计任职时间：10年又279天 任职起始日期：2014-11-18 现任基金公司:工银瑞信基金管理有限公司 现任基金资产 在管基金最佳 总规模 ...

金融界2025年8月20日消息，工银前沿医疗股票A(001717) 最新净值3.4760元，下跌0.52%。该基金近1个 月收益率1.67%，同类排名964|1023；近6个月收益率30.63%，同类排名115|984；今年来收益率 32.12%，同类排名222|974。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。 工银前沿医疗股票A股票持仓前十占比合计59.44%，分别为：恒瑞医药（9.51%）、科伦药业 （9.16%）、 ...

工银前沿医疗股票A股票持仓前十占比合计59.44%，分别为：恒瑞医药（9.51%）、科伦药业 （9.16%）、信立泰（6.70%）、海思科（6.02%）、百济神州-U（5.96%）、新诺威（5.86%）、泽璟制 药-U（4.77%）、药明康德（4.60%）、华东医药（4.57%）、荣昌生物（2.29%）。 公开资料显示，工银前沿医疗股票A基金成立于2016年2月3日，截至2025年6月30日，工银前沿医疗股 票A规模93.30亿元，基金经理为赵蓓。 金融界2025年8月7日消息，工银前沿医疗股票A(001717) 最新净值3.3960元，下跌2.19%。该基金近1个 月收益率10.22%，同类排名252|1022；近6个月收益率29.67%，同类排名86|985；今年来收益率 29.08%，同类排名130|975。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock A fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1][3] - As of July 28, 2025, the latest net value of ICBC Frontier Medical Stock A is 3.4240 yuan, reflecting a growth of 3.04%. The fund's one-month return is 13.45%, six-month return is 32.00%, and year-to-date return is 30.14% [1] - The fund's top ten stock holdings account for a total of 59.44%, with significant investments in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and others [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan. The fund manager is Zhao Bei [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014 and currently holds multiple managerial positions within ICBC Credit Suisse Asset Management [2]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.3810 yuan, reflecting a decline of 1.11% [1] - The fund has achieved a return of 12.70% over the past month, ranking 117 out of 717 in its category; a return of 29.84% over the past six months, ranking 54 out of 704; and a year-to-date return of 28.51%, ranking 62 out of 702 [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xin Li Tai (6.70%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan, managed by fund manager Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having worked in various roles since joining ICBC Credit Suisse in 2010 [2]

Group 1 - The core viewpoint of the article highlights the performance and outlook of the AI Fund ICBC Frontier Medical Stock A, which reported a profit of 780 million yuan in Q2 2025, with a net value growth rate of 9% [2] - As of July 18, 2025, the fund's unit net value was 3.419 yuan, and the fund manager, Zhao Bei, oversees five funds that have all achieved positive returns over the past year [2] - The fund's management indicates a stabilization trend in consumer medical demand since the first half of 2025, with ongoing observations needed for sustained recovery [2] Group 2 - The fund's recent performance metrics show a three-month net value growth rate of 21.85%, a six-month growth rate of 33.03%, and a one-year growth rate of 29.61%, ranking it 36/54, 35/54, and 37/53 among comparable funds respectively [3] - The fund's three-year Sharpe ratio is -0.0663, placing it 24/46 among comparable funds, while the maximum drawdown over the same period is 34.88%, ranking 33/46 [8][10] - As of Q2 2025, the fund's total assets amounted to 9.33 billion yuan, with the top ten holdings including major pharmaceutical companies such as Heng Rui Medicine and BeiGene [15][18]

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock A fund, which has shown a recent net value increase of 1.05% and notable returns over various time frames [1] - The fund's recent one-month return is -1.03%, ranking 791 out of 826 in its category, while its six-month return is 23.38%, ranking 99 out of 804, and year-to-date return is 20.94%, ranking 101 out of 801 [1] - The top ten stock holdings of the fund account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager, Zhao Bei, has extensive experience in the healthcare sector, having held various positions since joining ICBC Credit Suisse Asset Management in 2010 [2]

Group 1 - The core point of the article highlights the performance and holdings of the Industrial Bank's Frontier Medical Stock A fund, which has a recent net value of 3.0810 yuan, down by 2.50% [1] - The fund's performance over the past month shows a return of -1.41%, ranking 584 out of 646 in its category; over the past six months, it has achieved a return of 21.49%, ranking 76 out of 625; and since the beginning of the year, it has returned 17.10%, ranking 85 out of 623 [1] - The top ten holdings of the fund account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] Group 2 - The Industrial Bank's Frontier Medical Stock A fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan, managed by Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having served in various roles since joining Industrial Bank in 2010, including as the head of the healthcare research team [2]

Group 1 - The core point of the news is the performance and holdings of the Industrial Bank's Frontier Medical Stock A fund, which has shown a recent decline in net value but positive returns over various time frames [1] - As of June 20, 2025, the latest net value of the fund is 3.0000 yuan, reflecting a decrease of 0.60% [1] - The fund's one-month return is 1.83%, ranking 193 out of 1019 in its category; the six-month return is 11.15%, ranking 122 out of 986; and the year-to-date return is 14.03%, ranking 107 out of 990 [1] Group 2 - The top ten holdings of the fund account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] - The fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector and has been managing this fund since its inception [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock A fund, which has shown significant returns over various time frames [1] - As of June 16, 2025, the latest net value of ICBC Frontier Medical Stock A is 3.1910 yuan, reflecting a decrease of 0.75% [1] - The fund's one-month return is 12.08%, ranking 59 out of 941 in its category; the six-month return is 18.05%, ranking 81 out of 918; and the year-to-date return is 21.28%, ranking 78 out of 922 [1] Group 2 - The top ten holdings of ICBC Frontier Medical Stock A account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] - The fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector and has been managing this fund since its inception [2]